Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCision to offer new CoolBox XT technology
The CoolBox XT technology, which does not require power, can be used as an alternative to the ice bucket. The patent-pending technology reduces ice-related issues such as sample
The CoolBox XT technology, which does not require power, can be used as an alternative to the ice bucket. The patent-pending technology reduces ice-related issues such as sample
The patent at issue in the case covers the active ingredient in Nasonex, mometasone furoate monohydrate. The patent provides exclusivity for this form of mometasone until 3 April
Janssen-Cilag International NV has also sent a type II variation to the European Medicines Agency (EMA) for approval. The two applications are intended to increase the uses of
CVT-301 provides immediate onset of a large and precise dose of L-dopa. The Phase 2a study is a randomized, placebo-controlled, single dose, cross-over design that will feature the
The total acquistion value is considered to be $312m and around $114m based on certain pre-determined milestones which also includes revenue targets. As of 31March 2012, US-based OraPharma’s
The licence will help Life Technologies to expand its products and services for the iPS cell research community. The agreement also allows Life Technologies leverages to sell iPS
Shanghai Clinical Research Centre(SCRC), Quintiles’ strategic partner in the China-based lab initiative, will provide lab testing services to customers as part of the agreement. Quintiles will invest $14m
The trial, which involves 96 patients, is being carried out under an agreement with The Centre Hospitalise Universities dangers ("CHI dangers"). The 18-month, double-blind, placebo-controlled study will be
According to the 2011 CRN Consumer Survey on Dietary Supplements, overall, 69% of US adults use dietary supplements. Nouveau Life CEO Melissa Walker said the data point alone
The aim of the trial will be to know whether closed oregovomab in relation with front-line chemotherapy will generate the same or an improved immunity and clinical response.